(NASDAQ: RPTX) Repare Therapeutics's forecast annual revenue growth rate of -23.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Repare Therapeutics's revenue in 2024 is $51,133,000.On average, 6 Wall Street analysts forecast RPTX's revenue for 2024 to be $1,858,799,812, with the lowest RPTX revenue forecast at $1,535,431,243, and the highest RPTX revenue forecast at $2,235,655,381. On average, 2 Wall Street analysts forecast RPTX's revenue for 2025 to be $1,240,366,915, with the lowest RPTX revenue forecast at $793,446,749, and the highest RPTX revenue forecast at $1,687,287,080.
In 2026, RPTX is forecast to generate $1,029,456,030 in revenue, with the lowest revenue forecast at $793,446,749 and the highest revenue forecast at $1,265,465,310.